Drug safety in Crohn's disease therapy

Digestion. 2007;76(2):161-8. doi: 10.1159/000111031. Epub 2008 Feb 7.

Abstract

The management of Crohn's disease usually consists of a succession of short-term acute phase treatments followed by a long-term maintenance therapy. Above all the most frequent adverse events and the data on the long-term safety of the therapeutic arsenal available to the physician will be taken into consideration. The drugs described in this article include 5-ASA compounds, antibiotics (metronidazole, ciprofloxacin and rifaximin), corticosteroids (budesonide, prednisone and equivalents), thiopurines (azathioprine and 6-mercaptopurine), methotrexate, anti-tumor necrosis factor inhibitors (infliximab, adalimumab, certolizumab), natalizumab, anticalcineurin inhibitors (cyclosporine, tacrolimus) and mycophenolate mofetil.

Publication types

  • Review

MeSH terms

  • Adrenal Cortex Hormones / standards
  • Adrenal Cortex Hormones / therapeutic use*
  • Anti-Bacterial Agents / standards
  • Anti-Bacterial Agents / therapeutic use*
  • Anti-Inflammatory Agents, Non-Steroidal / standards
  • Anti-Inflammatory Agents, Non-Steroidal / therapeutic use*
  • Crohn Disease / drug therapy*
  • Dose-Response Relationship, Drug
  • Humans
  • Immunosuppressive Agents / standards
  • Immunosuppressive Agents / therapeutic use*
  • Risk Factors
  • Safety

Substances

  • Adrenal Cortex Hormones
  • Anti-Bacterial Agents
  • Anti-Inflammatory Agents, Non-Steroidal
  • Immunosuppressive Agents